Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcutis Biotherapeutics Inc ARQT

Healthcare Biotechnology
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment... see more

Recent & Breaking News (NDAQ:ARQT)

Arcutis Announces Appointment of Keith Leonard to Board of Directors

GlobeNewswire September 2, 2021

Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis

GlobeNewswire August 25, 2021

Bruce Binkowitz Joins Arcutis as Vice President of Biometrics

GlobeNewswire August 23, 2021

Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 5, 2021

Arcutis Announces Additions to its Investor Relations and Communications Team

GlobeNewswire August 2, 2021

Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis

GlobeNewswire July 21, 2021

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis

GlobeNewswire July 12, 2021

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

GlobeNewswire July 1, 2021

Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies

GlobeNewswire June 23, 2021

Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors

GlobeNewswire June 9, 2021

Rajvir Madan Joins Arcutis as Chief Digital and Information Officer

GlobeNewswire June 1, 2021

Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021

GlobeNewswire May 6, 2021

Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 4, 2021

Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium

GlobeNewswire May 3, 2021

Arcutis to Present at the 2021 Truist Securities Life Sciences Summit

GlobeNewswire April 28, 2021

Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021

GlobeNewswire April 23, 2021

Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX)

GlobeNewswire April 19, 2021

Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years

GlobeNewswire April 12, 2021

Arcutis Announces Updates to its Executive Team

GlobeNewswire March 26, 2021

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

GlobeNewswire March 18, 2021